Brean Capital Reiterates Buy On Repros As There Are No Surprises In 3Q14 Report
Brean Capital analyst Jonathan Aschoff is out today with his second note this week on Repros Therapeutics (NASDAQ:RPRX) maintaining a Buy rating, with a $41 price target, following the company’s third-quarter results.
Aschoff noted, “Repros ended 3Q14 with about $53 million in cash, far more than is needed to file the Androxal NDA. Repros reported interest income for 3Q14 of $2k and EPS of $(0.32).”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jonathan Aschoff has a total average return of 12.7% and a 62.0% success rate. Aschoff has a -1.0% average return when recommending RPRX, and is ranked #173 out of 3367 analysts.